Home
Up
What's New
News
What To Do First
On Line Support List
Potential Treatments
Symptoms Mgmt
Diagnostic Tests
Information Resources
FAQ

 

 

Click here to Return to Proven Treatments

 

CHEMOTHERAPY HOME

The side effects of chemotherapy are covered on the symptoms management page.

The use of ports can be found by reading patients' experiences with Chemotherapy ports.

Introduction

Chemotherapy Updates.  Go to this page for links to updates on 2004 chemotherapy studies and also a link to 2005 updates.  These are in easy to read table format. As new studies are published, their data will also be added on the update page.

Mitoxantrone and Mitoxantrone combinations for 2nd line chemotherapy, February 2007.

Combined Hormonal Ablation/Chemotherapy for High Risk Prostate Cancer. March 2002.

A Patient's Perspective on Chemotherapy - Part 1

A Patient's Perspective on Chemotherapy - Part 2

Chemotherapy for HRPC - Part 3. A Patient's Review of ASCO 2001 and Current Journal Abstracts.  12 May 2001.

Can Chemotherapy Extend Survival for Hormone Refractory Prostate Cancer Patients? A Patients Perspective, February 2002. This paper outlines sequential chemotherapies.

Intermittent Chemotherapy -- Leukine, Retinoids and Thalidomide for Extending the Off Period. This paper discusses a possible way of reducing the side effects of chemotherapy. October 2004.

Thinking Out-of-the-Box. A patient’s musings about whether our conventional treatment for advanced prostate cancer with chemotherapy can be modified to prolong quality survival. March 2002.

Taxol Combinations Including Taxol and High Dose Calcitriol.  Added April 2006.

Taxol or Taxotere? A comparison of  these two chemotherapy drugs from a patient 'friendliness' point of view. Bill Aishman March 2003.

AbraxaneTM , albumin nanoparticle paclitaxel (Taxol). H. Hansen, 2/6/07.

Avastin (Bevacizumab) with Taxotere (Docetaxel). This paper also includes some information on the phase III trial of this combination as well as the phase II study where thalidomide was also added for a double antiangiogenesis combination.  Howard Hansen 8/13/2008.

Calcitriol as an Antitumor Agent and Enhancer of Chemotherapy Agents - A Patients Perspective. July 2003.

Cyclophosphamide (Cytoxan®), an oral or I-V chemotherapy used as a first line or ≥ 2nd line chemotherapy.  Suitable for low-dose metronomic dosing.

Revlimid (lenalidomide). This paper covers Revlimid in combination with docetaxel and in combination with leukine. H. Hansen 12/18/2007.

Gemcitabine (Gemzar) for HRPC.  Single agent gemcitabine and gemcitabine combined with other chemotherapeutic drugs. Consider for use as a 2nd or 3rd line treatment. Howard Hansen 2/16/08.

Vinorelbine (Navelbine) for HRPC. Single agent vinorelbine, taxotere plus vinorelbine, emcyt plus vinorelbine, taxol plus vinorelbine, vinorelbine plus adriamycin, vinorelbine plus emcyt plus mitoxantrone.  Howard Hansen 2/12/08.

Xeloda (Capecitabine) for HRPC. This paper examines Xeloda by itself and in combination with taxotere.  Howard Hansen 1/5/07.

 

[Top]

This information is provided for educational purposes only and does not replace or amend professional medical advice. Unless otherwise stated and credited, the content of www.hrpca.org is by and the opinion of and copyright © 2001-2008 by H. Hansen. All Rights Reserved.  Our policy regarding privacy,  right to reprint and contact information are at About Us. We are a 501(c)(3) not-for-profit public charity.